Dutch drugmaker Prosensa jumps 54 percent in U.S. stock market debut

(Reuters) – Dutch drugmaker Prosensa Holding received a buoyant welcome in its market debut on the Nasdaq, a day after U.S. health regulators granted a “breakthrough status” to its drug to treat a rare disease. Prosensa’s shares opened $7 above its initial public offering price of $13 and were up 46 percent at $19.05 about an hour after they started trading. Prosensa developed drisapersen in partnership with GlaxoSmithKline Plc to treat Duchenne Muscular Dystrophy (DMD), a muscle-wasting disorder that affects one in every 3,500 newborn boys and has no available cure. …